TY - JOUR
T1 - Novel dental implant modifications with two-staged double benefits for preventing infection and promoting osseointegration in vivo and in vitro
AU - Huang, Xiaoyu
AU - Ge, Yang
AU - Yang, Bina
AU - Han, Qi
AU - Zhou, Wen
AU - Liang, Jingou
AU - Li, Mingyun
AU - Peng, Xian
AU - Ren, Biao
AU - Yang, Bangcheng
AU - Weir, Michael D.
AU - Guo, Qiang
AU - Wang, Haohao
AU - Zhou, Xinxuan
AU - Lu, Xugang
AU - Oates, Thomas W.
AU - Xu, Hockin H.K.
AU - Deng, Dongmei
AU - Zhou, Xuedong
AU - Cheng, Lei
N1 - Funding Information:
This research was supported by the National Key Research and Development Program of China ( 2016YFC1102700 , 2016YFC1102701 X.Z), National Natural Science Foundation of China ( 81870759 , 82071106 , L.C), Innovative Research Team Program of Sichuan Province (L.C).
Publisher Copyright:
© 2021 The Authors
PY - 2021/12
Y1 - 2021/12
N2 - Peri-implantitis are a major problem causing implant failure these days. Accordingly, anti-infection during the early stage and subsequent promotion of osseointegration are two main key factors to solve this issue. Micro-arc oxidation (MAO) treatment is a way to form an oxidation film on the surface of metallic materials. The method shows good osteogenic properties but weak antibacterial effect. Therefore, we developed combined strategies to combat severe peri-implantitis, which included the use of a novel compound, PD, comprising dendrimers poly(amidoamine) (PAMAM) loading dimethylaminododecyl methacrylate (DMADDM) as well as MAO treatment. Here, we explored the chemical properties of the novel compound PD, and proved that this compound was successfully synthesized, with the loading efficiency and encapsulation efficiency of 23.91% and 31.42%, respectively. We further report the two-stage double benefits capability of PD + MAO: (1) in the first stage, PD + MAO could decrease the adherence and development of biofilms by releasing DMADDM in the highly infected first stage after implant surgery both in vitro and in vivo; (2) in the second stage, PD + MAO indicated mighty anti-infection and osteoconductive characteristics in a rat model of peri-implantitis in vivo. This study first reports the two-staged, double benefits of PD + MAO, and demonstrates its potential in clinical applications for inhibiting peri-implantitis, especially in patients with severe infection risk.
AB - Peri-implantitis are a major problem causing implant failure these days. Accordingly, anti-infection during the early stage and subsequent promotion of osseointegration are two main key factors to solve this issue. Micro-arc oxidation (MAO) treatment is a way to form an oxidation film on the surface of metallic materials. The method shows good osteogenic properties but weak antibacterial effect. Therefore, we developed combined strategies to combat severe peri-implantitis, which included the use of a novel compound, PD, comprising dendrimers poly(amidoamine) (PAMAM) loading dimethylaminododecyl methacrylate (DMADDM) as well as MAO treatment. Here, we explored the chemical properties of the novel compound PD, and proved that this compound was successfully synthesized, with the loading efficiency and encapsulation efficiency of 23.91% and 31.42%, respectively. We further report the two-stage double benefits capability of PD + MAO: (1) in the first stage, PD + MAO could decrease the adherence and development of biofilms by releasing DMADDM in the highly infected first stage after implant surgery both in vitro and in vivo; (2) in the second stage, PD + MAO indicated mighty anti-infection and osteoconductive characteristics in a rat model of peri-implantitis in vivo. This study first reports the two-staged, double benefits of PD + MAO, and demonstrates its potential in clinical applications for inhibiting peri-implantitis, especially in patients with severe infection risk.
KW - Animal model
KW - Bioactive and therapeutic
KW - Dimethylaminododecyl methacrylate
KW - Osseointegration
KW - Peri-implantitis
UR - http://www.scopus.com/inward/record.url?scp=85105823346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105823346&partnerID=8YFLogxK
U2 - 10.1016/j.bioactmat.2021.04.041
DO - 10.1016/j.bioactmat.2021.04.041
M3 - Article
AN - SCOPUS:85105823346
SN - 2452-199X
VL - 6
SP - 4568
EP - 4579
JO - Bioactive Materials
JF - Bioactive Materials
IS - 12
ER -
